Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Neutral Recommendation

Citigroup initiated coverage of BridgeBio Pharma (NasdaqGS: BBIO) with a Neutral rating on May 19, 2026. The analyst price forecast implies 59.71% upside, suggesting a constructive valuation view despite the neutral recommendation. The note is primarily analyst commentary and is likely to have limited near-term market impact.

Analysis

Citigroup initiated coverage of BridgeBio Pharma (NasdaqGS: BBIO) with a Neutral rating on May 19, 2026. The analyst price forecast implies 59.71% upside, suggesting a constructive valuation view despite the neutral recommendation. The note is primarily analyst commentary and is likely to have limited near-term market impact.